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Multivariate analysis of febrile neutropenia occurrence in
patients with non-Hodgkin lymphoma: data from the INC-EU
Prospective Observational European Neutropenia Study
Chemotherapy-induced neutropenia (CIN) is a frequent and
potentially serious adverse effect of cancer treatment (Dale
et al, 2003). Lymphoma patients with CIN who develop febrile
neutropenia (FN) are typically hospitalised and treated with
intravenous antibiotics (Dale et al, 2003; Crawford et al, 2004;
Nijhuis et al, 2005; Aapro et al, 2006; Klastersky & Paesmans,
2007). A common response to CIN is to reduce or delay
delivery of chemotherapy treatment (Dale et al, 2003;
Schwenkglenks et al, 2006); however, decreased dose intensity
has been associated with increased morbidity and mortality in
patients treated with curative intent (Kwak et al, 1990; Lepage
et al, 1993; Bonadonna et al, 1995; Budman et al, 1998; Bosly
et al, 2008; Pettengell et al, 2008a); indicating that patient
outcome is improved when the intensity of chemotherapy
treatment is optimal (Bosly et al, 2008).
Colony-stimulating factors (CSFs) are used to reduce the risk
of developing neutropenic complications and to facilitate
delivery of planned chemotherapy dose (Komrokji & Lyman,
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Summary
Myelosuppression, particularly febrile neutropenia (FN), are serious dose-
limiting toxicities that occur frequently during the ﬁrst cycle of
chemotherapy. Identifying patients most at risk of developing FN might
help physicians to target prophylactic treatment with colony-stimulating
factor (CSF), in order to decrease the incidence, or duration, of
myelosuppression and facilitate delivery of chemotherapy as planned. We
present a risk model for FN occurrence in the ﬁrst cycle of chemotherapy,
based on a subgroup of 240 patients with non-Hodgkin lymphoma (NHL)
enroled in our European prospective observational study. Eligible patients
had an International Prognostic Index of 0–3, and were scheduled to receive a
new myelosuppressive chemotherapy regimen with at least four cycles.
Clinically relevant factors signiﬁcantly associated with cycle 1 FN were older
age, increasing planned cyclophosphamide dose, a history of previous
chemotherapy, a history of recent infection, and low baseline albumin
(<35 g/l). Prophylactic CSF use and higher weight were associated with a
signiﬁcant protective effect. The model had high sensitivity (81%) and
speciﬁcity (80%). Our model, together with treatment guidelines, may
rationalise the clinical decision of whether to support patients with CSF
primary prophylaxis based on their risk factor proﬁle. Further validation is
required.
Keywords: Non-Hodgkin lymphoma, neutropenia, chemotherapy, risk fac-
tors.
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to identify those patients that should be supported with
prophylactic CSF are faced with an array of patient-related and
treatment-related factors to consider. Current guidelines
recommend CSF support for chemotherapy treatment regi-
mens associated with a high risk of FN (>20%) (Aapro et al,
2006; Smith et al, 2006). One such regimen is combination
chemotherapy with cyclophosphamide, doxorubicin, vincris-
tine and prednisone (CHOP), which has long been the standard
treatment for patients with aggressive non-Hodgkin lymphoma
(NHL) (Fisher et al, 1993). The addition of rituximab to the
CHOP regimen (R-CHOP) has further improved patient
outcomes (Coifﬁer et al, 2002; Pfreundschuh et al, 2006;
National Comprehensive Cancer Network Inc, 2008a), making
R-CHOP the current standard of care (National Comprehen-
sive Cancer Network Inc, 2008a). CHOP-like chemotherapy
carries a signiﬁcant risk of FN (17–50%) (Morrison et al, 2001;
Lyman et al, 2003; Osby et al, 2003; Aapro et al, 2006; Bosly
et al, 2008; Pettengell et al, 2008b). In addition to the risk
associated with the chemotherapy regimen, other risk factors
should be considered in order to determine the patient’s overall
FN risk (Aapro et al, 2006; Smith et al, 2006; National
Comprehensive Cancer Network Inc, 2008b).
Several retrospective studies have identiﬁed potential risk
factors for FN in lymphoma patients, including older age, low
baseline blood cell counts, low serum albumin, anaemia,
abnormal bone marrow, increased lactate dehydrogenase
(LDH), co-morbid renal, cardiovascular or hepatic disease,
full or high-risk planned chemotherapy regimen, and lack of
CSF prophylaxis (Lyman & Delgado, 2003; Lyman et al, 2005;
Rabinowitz et al, 2006; Teegala et al, 2007). However, it is not
possible to give a weighting to these risk factors and accurately
determine their individual importance. The potential for risk
factors identiﬁed in retrospective studies to guide targeted CSF
use needs to be validated in prospective investigations.
Early, prospective clinical models in lymphoma patients not
receiving CSF prophylaxis identiﬁed high levels of serum LDH
and tumour necrosis factor (TNF) and bone marrow involve-
ment as risk factors for FN (Intragumtornchai et al, 2000; Voog
et al, 2000). Data from several large prospective registries have
led to the development of risk models for chemotherapy-
induced FN, andtherisk factorsthey haveidentiﬁed arebroadly
consistentwiththosehighlightedbyretrospectivestudies(Casas
et al, 2006; Lyman et al, 2006; Shayne et al, 2007a). However,
these studies were in patients with solid tumours (Casas et al,
2006) or in patients with solid tumours or lymphoma (Lyman
et al, 2006; Shayne et al, 2007a), and therefore did not specif-
ically examine the risk of FN in lymphoma patients.
Several studies have demonstrated that the risk of FN is
greatest in the ﬁrst cycle of chemotherapy, with >50% of
patients who develop FN experiencing an episode during cycle
one (Lyman & Delgado, 2003; Lyman et al, 2003). The Impact
of Neutropenia in Chemotherapy – European Study Group
(INC-EU) Prospective Observational European Neutropenia
Study was conducted to assess the incidence and predictors of
neutropenia, FN and reduced chemotherapy administration
for breast cancer and lymphoma patients in European
practices. Multivariate regression models for lymphoma
patients indicated that ﬁrst cycle FN, age ‡65 years, disease
status, and type of chemotherapy regimen predicted low
relative dose intensity (RDI), while primary prophylaxis with
CSF was protective (Pettengell et al, 2008b).
Here we present a subgroup analysis of NHL patients from
the INC-EU prospective study with the aim of establishing a
multivariate risk model of FN occurrence in the ﬁrst cycle of
chemotherapy. Such models may help to target high-risk
patients for prophylactic treatment in order to decrease the
incidence of myelosuppression and enable full-dose chemo-
therapy to be delivered on schedule.
Methods
Study design and patient selection
Data were obtained for 749 patients with histologically
conﬁrmed breast cancer, NHL and Hodgkin lymphoma (HL)
who were enrolled in the INC-EU Prospective Observational
European Neutropenia Study between January 2004 and May
2005. A subset of 240 patients with NHL were included in this
sub-analysis. The study was conducted in 66 centres in
Belgium, France, Germany, Spain and the UK. Of these, 39
centres contributed NHL patients for this subanalysis. Ethical
approval was obtained from the institutional review boards of
all centres. Patients with NHL and an International Prognostic
Index (IPI) of 0–3, and who were scheduled to receive a new
myelosuppressive chemotherapy regimen with at least four
cycles, were eligible for inclusion. All participants provided
their informed consent. Further details of the overall study
design and patient selection have been described previously
(Pettengell et al, 2008b).
Statistical methods
Multivariate logistic regression models of FN occurrence in
cycle 1 were developed. In line with established deﬁnitions (e.g.
National Comprehensive Cancer Network Inc, 2008b), FN was
deﬁned as Grade 4 CIN [absolute neutrophil count (ANC)
<0Æ5 · 10
9/l] and a body temperature ‡38 C. General esti-
mating equations (GEE)-based robust standard error (SE)
estimates were used to allow for clustering by study centre. The
impact of this choice was assessed by comparison with results
based on conventional SE estimates.
Candidate predictors were selected based on clinical and
statistical grounds (P £ 0Æ25 in univariate analysis). To rule
out circularity effects, potential direct correlates of the
dependent variables of interest were not used. In the model-
building process, main effects were identiﬁed by manually
exploring all plausible combinations of covariates. A model for
the occurrence of FN in any cycle of chemotherapy was also
developed using similar techniques.
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missing categories were introduced for candidate predictors
with more than 5% missing values. Concerns have been raised
that this approach can lead to biased estimation results,
particularly where covariates have a high proportion of missing
values and are strong confounders (Vach & Blettner, 1991;
Greenland & Finkle, 1995). Therefore, as an additional
sensitivity analysis, alternative models omitting all covariates
with more than 5% missing values were estimated and the
parameter estimates and standard errors for the remaining
covariates were assessed for deviations; these sensitivity
analyses did not reveal any relevant distortions.
The Hosmer–Lemeshow goodness of ﬁt test and plots of
mean observed versus mean predicted event probabilities, by
deciles of the linear predictor, were used to assess model ﬁt.
The risk of cycle 1 FN is presented as an odds ratio (OR) with
95% conﬁdence interval (CI). Predictive ability of the models
was characterised by sensitivity (percentage of the FN occur-
rences that were correctly predicted) and speciﬁcity (percent-
age of the FN non-occurrences that were correctly predicted),
positive predictive value (percentage of patients predicted to
have an FN who had FN), negative predictive value (percent-
age of patients predicted not to have an FN who did not have
FN), the area under the receiver operating characteristic
(ROC) curve, and the total proportion of correct predictions.
Additionally, in the absence of an independent validation
dataset, 10-fold cross-validation was performed. In a ﬁnal step,
the model was applied to hypothetical scenarios.
Variables considered for multivariate models
The following variables were considered for logistic regression
model building for both cycle 1 FN and any cycle FN: previous
chemotherapy (vs. chemotherapy-naı ¨ve); planned doses (for
sequential regimens, of ﬁrst part of chemotherapy); chemo-
therapy treatment within a clinical trial protocol; CSF
prophylaxis (for the purpose of statistical modelling, deﬁned
as any CSF use before a FN occurred); antibiotic prophylaxis
(for the purpose of statistical modelling, deﬁned as any
cotrimoxazole or quinoline use before a FN occurred) cancer
stage (Ann Arbor); number of haematology laboratory tests
before a grade IV CIN occurred; recent infection (<60 d prior
to start to chemotherapy); baseline ANC <3Æ0 · 10
9/l; baseline
white blood cell count (WBC) <5Æ0 · 10
9/l; baseline haemo-
globin <100 g/l; baseline glucose >8Æ8 mmol/l; baseline albu-
min <35 g/l; baseline total bilirubin >17Æ1 lmol/l; baseline
alkaline phosphatase >250 IU/l; number of comorbidities at
baseline; cardiac comorbidity at baseline; vascular comorbidity
at baseline; cardiovascular comorbidity at baseline; liver
disease at baseline; renal comorbidity at baseline; age; glomer-
ular ﬁltration rate (GFR; estimated using the Cockcroft-Gault
formula); height; weight; body surface area (BSA); and body
mass index (BMI). Assessment of comorbidities at baseline
used Medical Dictionary for Regulatory Activities (Med-
DRA
 )-coded medical history entries with the following
system organ class and preferred term names: cardiac dis-
orders; vascular disorders; renal and urinary disorders; hepa-
tobiliary disorders; infections and infestation; diabetes
mellitus. For the any cycle model, the following covariates
were also considered: planned dose intensities (for sequential
regimens, of ﬁrst part of chemotherapy); use of a dose dense
regimen (cycle length 2 weeks instead of 3 weeks); planned
cycle length; planned cycle number; dose reduction (‡10% of
planned dose of at least one drug in at least one cycle) before
FN occurred; and dose delay (a delay ‡4 d in at least one cycle)
before FN occurred.
Results
Patient and baseline disease characteristics are shown in
Table I. The majority of patients (75%) received a CHOP-21-
like treatment regimen and a high percentage (82%) of
patients received rituximab (Table II). An average of six
chemotherapy cycles were planned (mean 6Æ2, SD 1Æ5). Overall,
28% of patients received primary CSF prophylaxis and 29%
had other CSF use. CSFs used were: ﬁlgrastim, 40%; pegﬁl-
grastim, 34%; lenograstim, 10%. The remaining 16% of
patients with any CSF use received two or three of these
substances. Primary antibiotic prophylaxis with cotrimoxazole
was seen in 8% of patients and prophylaxis with quinolones in
14%. During cycle 1, FN occurred in 9% of patients and the
incidence of FN across all cycles of chemotherapy was 22%
(Fig 1). Grade IV CIN occurred in 35% of patients in cycle 1
and in 54% of patients across all cycles.
The results of the multivariate logistic regression analysis
used to model risk factors for cycle 1 FN are shown in
Table III. Clinically relevant factors that were signiﬁcantly
associated with cycle 1 FN were older age, increasing planned
cyclophosphamide dose, increasing planned etoposide dose, a
history of previous chemotherapy, a history of recent infection,
and low baseline albumin <35 g/l. Prophylactic CSF use and
higher weight were associated with a signiﬁcant protective
effect. The effect of antibiotic prophylaxis with cotrimoxazole
or quinolones remained non-signiﬁcant [OR (95% CI): 0Æ36
(0Æ08–1Æ62), P =0 Æ181] when added to the ﬁnal model.
Replacing age with GFR (to which it is inversely related) and
replacing weight with height yielded similar models.
The model correctly classiﬁed 192 of the 240 patients (80%).
The area under the ROC curve, which describes the ability of
the model to discriminate between those at risk from cycle 1
FN and those not at risk, was 0Æ86 (95% CI 0Æ79–0Æ94) (Fig 2).
(An area under the ROC curve of 0Æ5 implies an ability to
discriminate that is no better than chance, while a value of 1
represents perfect ability to discriminate). When the optimal
probability cut-off was used to predict cycle 1 FN, test
characteristics were: sensitivity 81%; speciﬁcity 80%; positive
predictive value 28% (proportion of patients classiﬁed as high
risk who suffered cycle 1 FN); negative predictive value 98%
(the proportion of patients classiﬁed as low FN risk who did
not suffer cycle 1 FN). Predictive ability was only slightly lower
INC-EU Prospective Febrile Neutropenia Risk Model
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ROC curve 0Æ78).
A similar model was developed to predict the risk of FN in
any cycle. In agreement with the ﬁrst cycle FN model, the
following factors were also signiﬁcantly associated with FN
occurrence in any cycle: age [OR (95% CI): 1Æ79 (1Æ16–2Æ78)
per additional 10 years, P =0 Æ009]; increasing planned cyclo-
phosphamide dose [OR (95% CI): 1Æ33 (1Æ16–1Æ52) per
additional 50 mg/m
2, P <0 Æ001]; increasing planned etopo-
side dose [OR (95% CI): 1Æ88 (1Æ10–3Æ20) per additional
50 mg/m
2, P =0 Æ021]; and recent infection [OR (95% CI):
3Æ32 (1Æ03–10Æ71), P =0 Æ044]. Likewise, prophylactic CSF use
[OR (95% CI): 0Æ21 (0Æ10–0Æ44), P <0 Æ001] and higher weight
[OR (95% CI): 0Æ62 (0Æ44–0Æ88) per additional 10 kg,
P =0 Æ007] were associated with a signiﬁcant protective effect.
In addition, the following clinically relevant factors were
associated with a signiﬁcantly increased risk of any cycle FN:
low baseline ANC or WBC [ANC <3Æ0 · 10
9/l or WBC
<5 · 0
9/l; OR (95% CI): 4Æ18 (1Æ82–9Æ60), P =0 Æ001], high
baseline alkaline phosphatase [>250 IU/ml; OR (95% CI): 9Æ07
(1Æ41–58Æ50), P =0 Æ020], cardiovascular comorbidity [OR
(95% CI): 2Æ56 (1Æ04–6Æ29), P =0 Æ041], and increasing planned
cytarabine dose [OR (95% CI): 1Æ09 (1Æ05–1Æ13) per additional
50 mg/m
2, P <0 Æ001]. Use of a dose dense regimen (cycle
length 2 weeks instead of 3 weeks) may inﬂuence FN but did
not attain statistical signiﬁcance in our model [OR (95% CI):
1Æ84 (0Æ71–78), P =0 Æ208; see Discussion]. In the any cycle
model, dose reductions before an FN event occurred [OR
(95% CI): 0Æ24 (0Æ09–0Æ63), P =0 Æ004] and dose delays before
an FN event occurred [OR (95% CI): 0Æ17 (0Æ07–0Æ40),
P <0 Æ001] had a signiﬁcant protective effect against FN. In
contrast to the cycle 1 model, a history of chemotherapy [OR
(95% CI): 1Æ76 (0Æ49–6Æ36), P =0 Æ390] and low baseline
albumin [OR (95% CI): 1Æ62 (0Æ54–4Æ85) P =0 Æ391 when
added to the ﬁnal model] were non-signiﬁcant in the any cycle
model. Antibiotic prophylaxis showed no effect.
The any cycle model correctly classiﬁed 180 of 237 patients
(76%). The area under the ROC curve was 0Æ83 (95% CI 0Æ76–
0Æ90). When the optimal probability cut-off was used to
predict any cycle FN, test characteristics were: sensitivity 76%;
speciﬁcity 76%; positive predictive value 48%; negative
predictive value 92%. Predictive ability was slightly lower
under 10-fold cross-validation conditions (area under the
ROC curve 0Æ72).
Based on our models, the estimated risk of FN in cycle 1 or
any cycle during R-CHOP therapy for lymphoma (without
CSF prophylaxis) in a hypothetical 80 kg subject (average
weight of our male subsample) is shown in Table IV. The risk
of FN increased as the number of risk factors and age increased
in both models. Assigning a lower weight (e.g. 55 kg) to the
subject increased the risk for all possible scenarios shown in
Table IV.
Discussion
This study identiﬁed several clinically relevant factors that were
predictive or protective for cycle 1 FN. Patient and baseline
characteristics of older age and low baseline albumin were
predictive of cycle 1 FN, as were a clinical history of previous
chemotherapy or recent infection. Treatment characteristics,
speciﬁcally increasing planned chemotherapy dose, also sig-
niﬁcantly increased risk of cycle 1 FN. In contrast, higher
weight and prophylactic CSF use were associated with
signiﬁcant protective effects.
Older age (>65 years) is recognised as a risk factor for FN by
current European guidelines (Aapro et al, 2006). Indeed,
Table I. Patient and baseline disease characteristics (n = 240).
Characteristic
Age (years), mean ± SD (range) 63Æ2±1 2 Æ9 (17–90)
Female gender, n (%) 105 (43Æ8)
Height (cm), mean ± SD (range) 169Æ9 ± 9 (145–194)
Weight (kg), mean ± SD (range) 75 ± 16 (41–176)
BSA (m
2), mean ± SD (range) 1Æ8±0 Æ2( 1 Æ3–2Æ4)
GFR (ml/min), mean ± SD (range)* 82Æ9±3 0 Æ7; (21Æ6–264Æ0)
REAL classiﬁcation, n (%)
Diffuse large cell 154 (64Æ2)
Follicular 35 (14Æ6)
Mantle cell 12 (5Æ0)
Other 36 (15Æ0)
Unknown 3 (1Æ3)
Ann Arbor staging, n (%) 
I 42 (17Æ7)
II 62 (26Æ2)
III 39 (16Æ5)
IV 94 (39Æ7)
B symptoms, n (%)  113 (47Æ7)
IPI score, n (%) 
Low (0–1) 75 (31Æ7)
Intermediate (2–3) 132 (55Æ7)
High (‡4) 30 (12Æ7)
No. of comorbidities,
mean ± SD (range)
2Æ1±2 Æ1 (0–11)
Cardiovascular comorbidity, n (%) 65 (27Æ1)
Cardiac comorbidity n (%) 32 (13Æ3)
Liver comorbidity n (%) 5 (2Æ1)
Renal comorbidity n (%) 16 (6Æ7)
Recent infection, n (%)  11 (4Æ6)
Previous chemotherapy, n (%) 25 (10Æ4)
Low baseline albumin <35 g/dl, n (%)§ 54 (28Æ6)
High alkaline phosphatase
>250 IU/l, n (%)–
7( 3 Æ1)
BSA, body surface area; GFR, glomerular ﬁltration rate; IPI, Interna-
tional Prognostic Index; REAL, Revised European American Lym-
phoma; SD, standard deviation.
*n = 234.
 n = 237.
 <60 d prior to start of chemotherapy or ongoing infectious comor-
bidity.
§n = 189.
–n = 227.
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(EORTC) Elderly Guidelines recommend primary prophylaxis
with CSF for all elderly patients receiving curative CHOP-like
chemotherapy (Repetto et al, 2003). Although many of the
other patient risk factors identiﬁed in this study do not
necessarily reﬂect risk factors highlighted in the guidelines, it is
important to recognise that the EORTC guidelines (Aapro
et al, 2006) are based on a literature review of studies across
tumour types and are not speciﬁc for NHL.
The increased risk for cycle 1 FN associated with age and low
baseline albumin, and the protective effects of CSF prophy-
laxis, are consistent with data from retrospective studies
speciﬁc to NHL patients (Lyman & Delgado, 2003; Rabinowitz
et al, 2006; Teegala et al, 2007). An increased risk of FN in
patients with low serum albumin (Intragumtornchai et al,
2000) or higher cyclophosphamide dose (Voog et al, 2000) was
also reported in early prospective studies in this patient
population. Data on the potential relationship between prior
chemotherapy, weight or recent infection and the risk of cycle
1 FN in NHL is limited. However, a US nationwide prospective
cohort study of 3468 patients with solid tumours or lymphoma
identiﬁed prior chemotherapy and concurrent antibiotics as
risk factors for neutropenic complications in cycle 1. We
assume that antibiotics are not in themselves a risk factor for
FN, but that they are prescribed to patients who are perceived
to be at higher FN risk. Other risk factors identiﬁed in the US
study were the number of myelosuppressive agents, anthra-
cycline-based regimens, planned chemotherapy delivery >85%
of standard, cancer type, phenothiazines, abnormal alkaline
phosphatase, elevated bilirubin, low platelets, elevated glucose
Table II. Treatment characteristics.
Regimen n
Distribution
(%)
Primary CSF
prophylaxis
%  (n)
Other
CSF use*
%  (n)
Rituximab
administration
%  (n)
Total 240 100 27Æ5 (66) 28Æ8 (69) 81Æ7 (196)
CHOP-21-like  178 74Æ21 9 Æ7 (35) 34Æ3 (61) 86Æ5 (154)
CHOP-14-like 41 17Æ17 5 Æ6 (31) 9Æ8 (4) 65Æ9 (27)
ACVBP-like 9 3Æ86 6 Æ7 (6) 33Æ3 (3) 77Æ8 (7)
Other regimens 12 5Æ06 6 Æ7 (8) 8Æ3 (1) 66Æ7 (8)
ACVBP, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; CHOP, cyclo-
phosphamide, doxorubicin, vincristine and prednisone; CSF, colony-stimulating factor.
*Secondary prophylaxis or treatment.
 Includes six patients with a cycle length of 28 d.
 Denominator values for percentage calculations are the regimen n-values in column 2.
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Fig 1. Incidence of febrile neutropenia (FN) in cycle 1 and across all
cycles. Error bars represent 95% exact binomial conﬁdence intervals.
ACVBP = doxorubicin, cyclophosphamide, vindesine, bleomycin, and
prednisone. CHOP = cyclophosphamide, doxorubicin, vincristine and
prednisone. Data taken from Pettengell et al, 2008b.
Table III. Logistic regression model for predicting cycle 1 FN occur-
rence*.
Variable
Odds
ratio 95% CI P-value
Age  2Æ20 1Æ21–4Æ01 0Æ010
Weight  0Æ62 0Æ43–0Æ89 0Æ010
Previous chemotherapy§ 6Æ39 1Æ72–23Æ68 0Æ006
Planned cyclophosphamide dose§ 1Æ16 1Æ02–1Æ32 0Æ023
Planned cytarabine dose§ 1Æ06 0Æ98–1Æ16 0Æ151
Planned etoposide dose§ 1Æ59 1Æ20–2Æ11 0Æ001
CSF before an event occurred– 0Æ18 0Æ03–0Æ94 0Æ042
Baseline albumin low** 4Æ76 1Æ35–16Æ71 0Æ015
Baseline albumin missing** 0Æ52 0Æ09–2Æ99 0Æ464
Recent infection   3Æ07 0Æ99–9Æ52 0Æ052
CI, conﬁdence interval; CSF, colony-stimulating factor.
*Number of observations = 240, Wald v
2 =2 6 Æ59, prob > v
2 =0 Æ003,
log pseudolikelihood = )52Æ41.
 Per additional 10 years of age.
 Per additional 10 kg body weight.
§Planned doses in mg/m
2 body surface area; per additional 50 mg/m
2.
–Myelopoietic growth factor use before a FN occurred in cycle 1.
**Baseline albumin <35 g/dl, missing category introduced to avoid loss
of observations (sensitivity analyses did not reveal any relevant dis-
tortions with the use of this technique).
  During 60 d prior to chemotherapy or ongoing infectious comor-
bidity.
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(Lyman et al, 2006). Results from a subset of older patients
from the same registry (n = 1378) supported some of these
ﬁndings and additionally highlighted chemotherapy regimens
containing cyclophosphamide, etoposide or ifosfamide as
increasing the risk of early neutropenic events (Shayne et al,
2007a). Overall, the ﬁndings of the US prospective study
(Lyman et al, 2006; Shayne et al, 2007a) and the present study
were generally consistent and differences observed may be
related to the patient populations studied, treatment regimens
and sample size.
It is noteworthy that increasing planned chemotherapy dose
was predictive of FN in our model, in keeping with a
previously published model (Voog et al, 2000) and a recent
validated risk model that found that regimens containing
cyclophosphamide, etoposide or ifosfamide were associated
with an increased risk of early neutropenic events (Shayne
et al, 2007a). In our model, planned cyclophosphamide use
also correlated with the use of other anti-malignant agents,
which could potentially mask the contribution of these other
agents to the neutropenic potential of the chemotherapy
regimen. Planned etoposide dose was identiﬁed as a signiﬁcant
predictor of cycle 1 FN; however, very few patients received
this agent. Similarly, risk estimates for recent infection were
based on a small number of observations (11 patients) and
require careful interpretation. CSF primary prophylaxis had a
signiﬁcant protective effect against cycle 1 FN. The protective
effects of CSF have been validated previously (Komrokji &
Lyman, 2004; Aapro et al, 2006; Smith et al, 2006).
The high number of patients correctly classiﬁed by the model
(80%) suggests that it may have potential clinical utility. The
model showed good ability to discriminate between patients at
risk from cycle 1 FN and those not at risk. Model test
characteristics were comparable to, or better than, values
published for other risk models of neutropenia (Morrison et al,
2001; Lyman & Delgado, 2003; Lyman et al, 2006; Rabinowitz
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Fig 2. Receiver operating characteristic (ROC) curve for the multi-
variate analysis of factors predicting cycle 1 febrile neutropenia. Area
under ROC curve = 0Æ86 (95% conﬁdence interval 0Æ79–0Æ94).
Table IV. Estimated risk [%] of cycle 1 FN and
any cycle FN following R-CHOP treatment for
NHL (cycle length 3 weeks) in an 80 kg subject
(average weight of male subsample) according
to age and risk factor proﬁle. Estimated risks for
a lower assigned weight (55 kg) are given in
parentheses.
Cycle/risk factors
Age, years; weight 80 kg (55 kg), [%]
35 45 55 65 75
Cycle 1
None 0 (1) 1 (2) 1 (4) 3 (8) 6 (16)
Previous CT 2 (5) 3 (10) 7 (21) 15 (36) 28 (55)
Low albumin* 1 (4) 3 (8) 6 (16) 11 (30) 22 (48)
Recent infection  1 (2) 2 (5) 4 (11) 8 (21) 16 (37)
Previous CT + low albumin* 7 (20) 15 (36) 27 (55) 45 (73) 64 (86)
Previous CT + low albumin* +
recent infection 
19 (44) 34 (63) 54 (79) 72 (89) 85 (95)
Any cycle
None 5 (14) 8 (23) 14 (35) 22 (49) 34 (63)
Previous CT 8 (22) 14 (34) 22 (48) 34 (62) 48 (75)
ANC/WBC low  17 (41) 27 (55) 40 (69) 55 (80) 68 (88)
Alkaline phosphatase high  31 (60) 45 (73) 59 (83) 72 (90) 82 (94)
CV comorbidity 11 (30) 19 (43) 29 (57) 42 (71) 57 (81)
Recent infection  14 (35) 23 (49) 35 (64) 49 (76) 63 (85)
ANC/WBC low  + CV comorbidity 35 (64) 49 (76) 63 (85) 75 (91) 85 (95)
ANC/WBC low  + CV comorbidity +
recent infection 
64 (85) 76 (91) 85 (95) 91 (97) 95 (98)
ANC, absolute neutrophil count; CT, chemotherapy; CV, cardiovascular; WBC, white blood cell
count.
*Baseline albumin <35 g/l.
 During 60 d prior to treatment.
 Baseline ANC <3Æ0 · 10
9/l or WBC <5Æ0 · 10
9/l; baseline alkaline phosphatase >250 IU/ml.
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value showed that the model successfully identiﬁed patients at
low risk of developing FN. The 28% positive predictive value
(PPV) indicated that the model identiﬁed as high risk some
patients who did not ultimately have a cycle 1 FN event. While
a higher PPV is desirable, it should be remembered that the
PPV in this setting was partially driven by a low absolute
frequency of cycle 1 FN events and that not every patient who is
at high risk of FN will actually experience FN.
The potential clinical utility of the model was explored by
applying our dataset to hypothetical scenarios of NHL patients
and estimating the risk of developing FN in cycle 1 or any
cycle. Whilst the presence of some risk factors alone (e.g. low
baseline albumin) did not predict a high risk of FN, a
combination of risk factors increased the predicted risk for
developing cycle 1 FN substantially. In addition, patient
characteristics of older age or lower weight increased the
predicted risk for developing cycle 1 FN for any of the given
risk factor scenarios.
Owing to the sample size, the relatively infrequent occur-
rence of cycle 1 FN (9%) and the high number of covariates
used, the logistic regression model generated has some
potential limitations in its ability to correctly assess the impact
of rare risk factors and there is the possibility of artefacts. This
caveat particularly applies to the effects of some comorbidities
and baseline laboratory abnormalities. The standard approach
to randomly split the study dataset into a training dataset (on
which the model is estimated) and a test dataset (on which the
model is validated) was considered to be inefﬁcient for the
same reasons. Ten-fold cross-validation has been shown to be
superior in small datasets (Goutte, 1997) and showed favour-
able results in the present case. However, additional validation
in an independent data set from a different population is
clearly required.
The any cycle model correctly classiﬁed 76% of patients, and
the test characteristics were comparable to a recent model of
risk for severe or febrile neutropenia across four cycles of
chemotherapy (Shayne et al, 2007b). The ﬁndings of the any
cycle model were similar to those observed with the cycle 1
model, with older age and increasing chemotherapy dose
identiﬁed as clinically relevant predictors of FN and prophy-
lactic CSF use and higher weight identiﬁed as being protective.
Although the use of a dose-dense regimen appeared predictive
of FN it did not attain statistical signiﬁcance, which is probably
because most patients (76%) treated with dose-dense regimens
received CSF support. In addition, dose reductions and dose
delays before an event occurred had a signiﬁcant protective
effect against FN. However, the practice of reducing or
delaying chemotherapy treatment in response to CIN and
FN has been questioned (Dale et al, 2003; Schwenkglenks et al,
2006), as decreased dose intensity has been associated with
increased morbidity and mortality (Kwak et al, 1990; Lepage
et al, 1993; Bonadonna et al, 1995; Budman et al, 1998; Bosly
et al, 2008; Pettengell et al, 2008a). Cardiac comorbidity was
also identiﬁed as a risk factor for any cycle FN, which is
consistent with current treatment guidelines (Aapro et al,
2006).
In summary, this study describes a prospective multivariate
risk model that was able to identify clinically relevant factors
that were predictive or protective of cycle 1 FN and correctly
identify a high proportion of patients at risk of ﬁrst cycle FN.
Our model, together with treatment guidelines, may rationalise
the clinical decision of whether to support patients with CSF
primary prophylaxis based on their risk factor proﬁle. Further
validation is required.
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